20/20 BioLabs enters exclusive technology license, access agreement with Rokit

20/20 BioLabs (AIDX) announced that it has entered into an exclusive U.S. technology license and access agreement with Rokit Healthcare. Under the agreement, 20/20 will integrate Rokit’s proprietary chronic kidney disease prediction algorithm into the 20/20 Longevity Platform, expanding its suite of biomarker-based disease-risk assessment tools. Under the agreement, Rokit agreed to reimburse 20/20 for one-third of mutually agreed sales and marketing expenses in exchange for a running royalty to Rokit on net sales of the combined product. The companies also anticipate negotiating a separate agreement under which Rokit may receive exclusive rights to commercialize 20/20’s longevity platform in Korea and potentially other East Asian markets.